• Vertex races to FDA after phase 3 kidney disease data impress analysts
• Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
• FDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection
  

• CVS, Humana & More Are Turning to Google’s AI Models
• AI Startups Are Tying Fees to Completed Tasks. Will Hospitals Buy In?
• For Anthropic, Pragmatism Is the More Trustworthy Position

• FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
• Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars
• BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

• Future of Health Tech: From Structured Data to Scalable AI
• Capturing the Vibe at ViVE 2026, Healthcare Executives Share Insights on Medication Adherence and Implementing AI
• Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and Claude Differs From HIPAA-Regulated Care

• Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
• FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
• Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'

• Opinion: AI could revolutionize antibiotics — but the market is standing in the way
• Third Way Health Secures $15M to Streamline Front-Office Operations for Medical Practices
• In­vestors are pump­ing mon­ey in­to AI tools for health in­sur­ers

• UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidate
• New cancer cases prompt Kyowa to discontinue late‑stage autoimmune disease program
• FDA details rationale for rejecting rare disease gene therapy from Regenxbio
  

• STAT+: FDA grants breakthrough status to generative AI chatbot
• AI Startups ROI Reckoning: What 4 VCs Say Matters Now
• Actionable AI in Clinical Settings: Trust and Transparency as the Core Operating System

[AI Generated Biotech and Pharma News]

• Ascendis wins FDA approval of dwarfism drug
• Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potential
• Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

• Senhwa's CX-4945 targets CK2 kinase with dual tumor and immune modulatory mechanisms; CellType's AI platform aims to expand indications and improve clinical success via multi-omics analysis and translational validation.
• Generate's $400M IPO signals strong investor confidence, driven by AI-designed pipelines including GB-0895, an AI-optimized TSLP inhibitor with potential to disrupt asthma treatment.
• hysiology remains foundational for translating AI and sensor data into clinically relevant therapies, aiding in anticipating off-target effects and enhancing regulatory acceptance.